Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel

Koffiekamer Terug naar discussie overzicht

Omega Diagnostics Group [ODX] - Ready to Launch the Rocket

454 Posts
Pagina: «« 1 ... 16 17 18 19 20 ... 23 »» | Laatste | Omlaag ↓
  1. Prijsman 25 januari 2021 12:39
    quote:

    DeZwarteRidder schreef op 24 januari 2021 15:00:

    [...]
    Dat is brutowinst en bovendien slechts tijdelijk.
    DZW gebruikt echter andere definitief voor "tijdelijk" Zo betekent "tijdelijk" bij meneer DZR ca. 1-2 jaar met mogelijke verlening. Dit gold ook voor Novacyt. Zie aldaar, dat heeft mij geen windeieren gelegd;-)!
  2. TheBiG 26 januari 2021 08:09
    WOW dubbele RNS!!

    www.voxmarkets.co.uk/rns/announcement...
    www.voxmarkets.co.uk/rns/announcement...

    Omega Diagnostics Gp - Update re AbC-19 Rapid Test

    Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes today's update from Abingdon Health plc (AIM: ABDX) ("Abingdon Health") regarding the AbC-19TM Rapid Test, confirming their expectations for future supply arrangements with the Department of Health and Social Care, the ongoing efforts to obtain regulatory approvals in a total of 27 geographies, and the ongoing work to build data the set(s) around the use-case for the AbC-19TM Rapid Test alongside vaccines.

    In addition, Omega will today announce the launch of its COVID-19 antibody lab-based testing service in Littleport, Cambridgeshire (see separate RNS Reach for details), using the Mologic ELISA1 antibody test. This service will be offered to commercial occupational health partners, clinics and health care professionals in the UK.

    Launch of COVID-19 antibody laboratory-based testing service

    This follows the successful CE marking of the capillary blood sample collection pack which is sent to healthcare professionals who then send the patient's sample back to the Company's laboratory, where the test is then run. Test results are then sent back to each healthcare professional who informs the patient of their result and provides advice as necessary.
  3. TheBiG 26 januari 2021 08:13
    Abingdon Health PLC

    www.voxmarkets.co.uk/rns/announcement...

    Half Year Trading Update

    Department of Health and Social Care
    Abingdon is pleased to report that it, along with UK-RTC consortium partners, completed the delivery of an order of 1 million AbC-19 anti-spike IgG devices to the Department of Health and Social Care (DHSC) on 8 January 2021. Regarding the current DHSC contract, as noted previously, this will expire on 14 February 2021 and, in-line with the Government's shift to a dynamic purchasing strategy, the Board expects that any future orders will be received via an application by the Company to future DHSC tender notices.

    International approvals for the AbC-19TM Rapid Test
    The Company is continuing to manufacture the AbC-19TM Rapid Test in anticipation of additional orders and to that end Abingdon's regulatory department is currently working with UK-RTC partners on regulatory approval in a total of 27 territories. As part of this regulatory approvals process, the Company continues to provide data to the US FDA ("Food and Drug Administration) to allow regulatory approval and in consultation with the FDA has provided additional performance data of the AbC-19TM Rapid Test versus PCR testing via a re-submission. The FDA has asked for additional data relating to PCR testing versus on-site finger-stick blood samples to allow focus on remote, or point-of-care testing which the Company expects to submit within four weeks.

    AbC-19TM Rapid Test compatibility with vaccines
    The Company believes that as an IgG neutralising antibody test, the AbC-19TM Rapid Test has a key role to play in mitigating the impact of the pandemic. The Company continues to work closely with commercial and academic partners to build the data set(s) around the use-case for the AbC-19TM Rapid Test alongside vaccines, and these will be published in due course.

  4. [verwijderd] 26 januari 2021 12:32
    Uiteraard bij publicatie van RNS gaat de koers omlaag. Dit is zoals het de afgelopen maanden altijd is geweest. Vervelend, maar komt wel weer goed.

    Vanochtend de 85 gbx aangetikt! De 100gbx komt weer in de buurt.
  5. Wiz@rD 27 januari 2021 17:07
    Wat een miserieaandeel. Op novacyt draadje zeggen ze dat uk conract heebft opgezegd met abbington
  6. [verwijderd] 29 januari 2021 10:34
    quote:

    Prijsman schreef op 28 januari 2021 15:08:

    Ongelofelijk wat met dit aandeel allemaal kan.
    Hier valt inderdaad niet tegenop te 'voorspellen/ hopen / rekenen'. Er zit totaal geen logica in dit koers verloop.
  7. TheBiG 2 februari 2021 09:16
    De stijging van gisteren zet weer leuk door! Inmiddels 0.70 GBX.
    Ben benieuwd waar we ergens gaan stranden dit jaar :-)

    This £912m tender is 200m tests to cover 1 MONTH!

    Fag packet:
    £912/200 = £4.56 a test
    50% margin = £2.28 GP
    £2.28 x 2m = £4.56m
    £4.56m x 52 = £237.1m
    Lowball PE x 4 = ~£950MCAP
    SP = £5.27
    Applying EBITDA to GP at ~85% = £201.5m
    Lowball PE x 4 = £806MCAP
    SP = £4.48

    twitter.com/Shredz90/status/135638114...
  8. [verwijderd] 2 februari 2021 10:00
    quote:

    TheBiG schreef op 2 februari 2021 09:16:

    De stijging van gisteren zet weer leuk door! Inmiddels 0.70 GBX.
    Ben benieuwd waar we ergens gaan stranden dit jaar :-)

    This £912m tender is 200m tests to cover 1 MONTH!

    Fag packet:
    £912/200 = £4.56 a test
    50% margin = £2.28 GP
    £2.28 x 2m = £4.56m
    £4.56m x 52 = £237.1m
    Lowball PE x 4 = ~£950MCAP
    SP = £5.27
    Applying EBITDA to GP at ~85% = £201.5m
    Lowball PE x 4 = £806MCAP
    SP = £4.48

    twitter.com/Shredz90/status/135638114...
    Haha, ja ik lees veel Twitter. En als je dat leest, gaat de koers 100% naar de £5,00. Al ben ik al blij als we naar £1,20-1,50 gaan.
  9. TheBiG 2 februari 2021 10:22
    quote:

    Fluxx schreef op 2 februari 2021 10:00:

    [...]

    Haha, ja ik lees veel Twitter. En als je dat leest, gaat de koers 100% naar de £5,00. Al ben ik al blij als we naar £1,20-1,50 gaan.
    Ik ben wat minder twitter gaan lezen maar een koers van 1.50 vind ik prima :-)
  10. forum rang 4 Louis7 7 februari 2021 09:38
    Three UK manufacturers selected to make rapid Covid tests.
    Push to develop domestic diagnostics industry and less reliance on foreign producers.

    February 7, 2021
    The UK government has selected three British companies to make rapid Covid-19 tests, as it seeks to shake off its reliance on foreign producers and create a domestic diagnostics industry that is prepared for future outbreaks of infectious disease.

    The department of health has selected Omega Diagnostics, SureScreen and Global Access Diagnostics to produce up to 2m lateral flow devices (LFDs) per week for the UK, according to two people briefed on the decision.

    The government has been intent on developing a domestic diagnostics industry since early last year when the Covid-19 crisis forced ministers to confront the lack of domestic sources of critical medical resources. In particular, it has been seeking to reduce its reliance on China for key imported goods as part of what has been dubbed “Project Defend”.

    Speaking in front of MPs on Wednesday, Baroness Dido Harding, the head of Test and Trace, said “there is very much an ambition to create a domestic UK manufacturing capacity” for LFDs, tests that provide results in under 30 minutes and have been the subject of fierce criticism.

    As part of this drive, the government last year paid the consulting firm PA Consulting £6.2m to find suitable British manufacturers of LFDs, and to help scale up manufacturing to reach 2m tests a day by April 2021.

    Unlike conventional polymerase chain reaction (PCR) tests, which look for the virus’s genetic material and can take up to a day to process, LFDs do not need to be analysed in a laboratory. The tests look for protein antigens that live on a virus’s surface and work by adding a liquid reagent to a saliva or nasal swab sample.

    £170m Cost of air freight of lateral flow devices tests from China to the UK since the beginning of the pandemic

    A ferocious scientific row has broken out about the accuracy and safety of these tests after several studies found they miss up to 60 per cent of active infections. One group of researchers continues to trumpet the devices as the only viable way of identifying the large portion of the public that experience no symptoms of the disease, while another says they are likely to kill many more people than they save.

    The government, which has doubled down on its rollout of LFDs in spite of the debate, has been almost entirely reliant on limited supplies from the US and China and is desperate to scale up domestic production.

    According to publicly available contracts, it has so far spent at least £1.5bn on the tests — and last month closed a tender worth a further £912m. The bulk of the spending has gone to US company Innova, which has received £1bn in contracts to procure hundreds of millions of devices which are manufactured in China.

    The department of health has spent £170m on air freight of these tests from China to the UK since the beginning of the pandemic, the contracts state.

    Global Access Diagnostics, which currently has 70 employees but is planning to hire another 210 by April, is a high volume manufacturing enterprise in Bedfordshire, which spun out from the diagnostics firm Mologic last year. It has received close to £1m in funding from the UK government and around £10m in equipment, according to Mark Radford, the company’s executive director.

    The company aims to expand its annual production of lateral flow tests from 40m to 250m by early May.

    Recommended
    Why supply chain diversification isn’t all that easy
    SureScreen, a firm based in the east Midlands which has so far supplied 2m lateral flow tests to the UK government, has received £11.3m in funding, according to publicly available contracts.

    Omega Diagnostics, which has bases in Scotland and Cambridge, SureScreen and Global Access Diagnostics all declined to comment on contracts with the government.

    The health department said: “We now have the largest diagnostic network in UK history, and our procurement strategy for testing ensures the UK has the supplies needed to support both the existing symptomatic testing and the expanding programme of asymptomatic testing being carried out.”

    amp.ft.com/content/37011547-c7b1-403b...
  11. Guuster 7 februari 2021 23:04
    Abee Louis. Ik kocht ze voor rond de 1 pond. Ik hoop dat we daar weer een beetje in de buurt gaan komen. Liefst iets erover heen :)
  12. TheBiG 8 februari 2021 11:21
    Mijn verkooporder inmiddels al 2x verhoogd. Gaat erg hard! Wachten is op het contract. We weten zeker dat er een deal gaat komen! Toch nog even wachten.
454 Posts
Pagina: «« 1 ... 16 17 18 19 20 ... 23 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 6.998
AB InBev 2 5.480
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.172
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.477
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.641
Aedifica 3 900
Aegon 3.258 322.640
AFC Ajax 538 7.086
Affimed NV 2 6.287
ageas 5.844 109.884
Agfa-Gevaert 14 2.048
Ahold 3.538 74.290
Air France - KLM 1.025 34.982
AIRBUS 1 11
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.032
Alfen 16 24.301
Allfunds Group 4 1.468
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 404
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.812
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.835 242.679
AMG 971 133.033
AMS 3 73
Amsterdam Commodities 305 6.685
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 482
Antonov 22.632 153.605
Aperam 92 14.886
Apollo Alternative Assets 1 17
Apple 5 380
Arcadis 252 8.731
Arcelor Mittal 2.033 320.484
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.287
Aroundtown SA 1 219
Arrowhead Research 5 9.715
Ascencio 1 26
ASIT biotech 2 697
ASMI 4.108 39.076
ASML 1.766 105.902
ASR Nederland 21 4.451
ATAI Life Sciences 1 7
Atenor Group 1 467
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.609
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.390

Macro & Bedrijfsagenda

  1. 05 februari

    1. Inkoopmanagersindex diensten januari def. (Jap)
    2. Inkoopmanagersindex diensten januari (Chi)
    3. Melexis cijfers vierde kwartaal
    4. Inkoopmanagersindex diensten januari def. (Dld)
    5. Inkoopmanagersindex diensten januari def. (eur)
    6. Inkoopmanagersindex diensten januari def. (VK)
    7. Producentenprijzen december (eur)
    8. GlaxoSmithKline Q4-cijfers (VK)
    9. Uber Q4-cijfers (VS)
    10. Hypotheekaanvragen wekelijks (VS)
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht